Form 4: Lexaria Bioscience Corp. Director Christopher Bunka Reports Stock Option Grant
SEC Form 4 Filing
Director Christopher Bunka reports acquisition of stock options and restricted stock award in Lexaria Bioscience Corp.
Summary
- Christopher Bunka, a director of Lexaria Bioscience Corp., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of 11,000 stock options with an exercise price of $1.04, exercisable from May 15, 2025, to May 15, 2030.
- Bunka directly owns 373,543 common shares and indirectly owns 254,412 common shares through a private holding company.
- He also holds various stock options with different exercise prices and expiration dates, totaling 184,834 options after the reported transaction.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.
Stakeholder Impact
- Shareholders are informed about the director's stake in the company through stock ownership and options.
Key Dates
| Date | Description |
|---|---|
| 04/26/2021 | Date of stock options grant with $3 exercise price expiring 04/26/2026 (26,000 shares) |
| 06/08/2021 | Date of stock options grant with $3 exercise price expiring 06/08/2026 (23,334 shares) |
| 09/01/2021 | Date of stock options grant with $3 exercise price expiring 09/01/2026 (15,000 shares) |
| 08/29/2022 | Date of stock options grant with $2.91 exercise price expiring 08/29/2027 (30,000 shares) |
| 10/26/2023 | Date of stock options grant with $1.15 exercise price expiring 10/26/2028 (30,000 shares) |
| 04/26/2024 | Date of stock options grant with $2.36 exercise price expiring 04/26/2029 (49,500 shares) |
| 05/15/2025 | Date of the reported transaction: acquisition of 11,000 stock options with $1.04 exercise price expiring 05/15/2030 |
| 07/07/2025 | Escrow provisions for 100,000 restricted stock award end |
Keywords
Form 4, stock options, beneficial ownership, Lexaria Bioscience Corp., Christopher Bunka, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.